TY - JOUR
T1 - Reevaluating Anti-Inflammatory Therapy
T2 - Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease
AU - Casso-Chapa, Bernardo
AU - Vazquez González, Norma Alicia
AU - Le, Nhat Tu
AU - Palaskas, Nicolas L.
AU - Nead, Kevin T.
AU - Eutsey, Lydia P.
AU - Samanthapudi, Venkata S.K.
AU - Osborn, Abigail M.
AU - Lee, Jonghae
AU - Mejia, Gilbert
AU - Hoang, Oanh
AU - Lin, Steven H.
AU - Deswal, Anita
AU - Herrmann, Joerg
AU - Wang, Guangyu
AU - Kirkland, James L.
AU - Krishnan, Sunil
AU - Wehrens, Xander H.T.
AU - Chini, Eduardo N.
AU - Yusuf, Syed Wamique
AU - Iliescu, Cezar A.
AU - Jain, Abhishek
AU - Burks, Jared K.
AU - Seeley, Erin
AU - Lorenzi, Philip L.
AU - Chau, Khanh M.
AU - Ostos Mendoza, Keila Carolina
AU - Grumbach, Isabella M.
AU - Brookes, Paul S.
AU - Hanssen, Nordin M.J.
AU - De Winther, Menno P.J.
AU - Yvan-Charvet, Laurent
AU - Kotla, Sivareddy
AU - Schadler, Keri
AU - Abe, Jun Ichi
N1 - Publisher Copyright:
© 2025 American Heart Association, Inc.
PY - 2025/1/16
Y1 - 2025/1/16
N2 - Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease, mitigating immune responses can decrease inflammation and slow atherosclerosis progression. Anti-inflammatory therapy, therefore, presents a unique dilemma for cancer survivors: while it may decrease cardiovascular risk, it might also promote cancer growth and metastasis by suppressing the immune response. Senescence presents a potentially targetable solution to this challenge; senescence increases the risk of both cancer therapy resistance and vascular disease. Exercise, notably, shows promise in delaying this premature senescence, potentially improving cancer outcomes and lowering vascular disease risk post-treatment. This review focuses on the long-term impact of cancer therapies on vascular health. We underscore the importance of modulating senescence to balance cancer treatment's effectiveness and its vascular impact, and we emphasize investigating the role of exercise-mediated suppression of senescence in improving cancer survivorship.
AB - Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease, mitigating immune responses can decrease inflammation and slow atherosclerosis progression. Anti-inflammatory therapy, therefore, presents a unique dilemma for cancer survivors: while it may decrease cardiovascular risk, it might also promote cancer growth and metastasis by suppressing the immune response. Senescence presents a potentially targetable solution to this challenge; senescence increases the risk of both cancer therapy resistance and vascular disease. Exercise, notably, shows promise in delaying this premature senescence, potentially improving cancer outcomes and lowering vascular disease risk post-treatment. This review focuses on the long-term impact of cancer therapies on vascular health. We underscore the importance of modulating senescence to balance cancer treatment's effectiveness and its vascular impact, and we emphasize investigating the role of exercise-mediated suppression of senescence in improving cancer survivorship.
KW - anti-inflammatory agents
KW - heart disease risk factors
KW - immune system
KW - immunity
KW - neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85215961949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85215961949&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.124.319870
DO - 10.1161/ATVBAHA.124.319870
M3 - Review article
C2 - 39817327
AN - SCOPUS:85215961949
SN - 1079-5642
VL - 45
SP - 372
EP - 385
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
IS - 3
ER -